rs77101217
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000492.4(CFTR):c.1477C>T(p.Gln493*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000059 in 1,611,422 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000064 ( 0 hom. )
Consequence
CFTR
NM_000492.4 stop_gained
NM_000492.4 stop_gained
Scores
5
1
1
Clinical Significance
Conservation
PhyloP100: 7.44
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 7-117559548-C-T is Pathogenic according to our data. Variant chr7-117559548-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 7107.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr7-117559548-C-T is described in Lovd as [Pathogenic]. Variant chr7-117559548-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CFTR | NM_000492.4 | c.1477C>T | p.Gln493* | stop_gained | 11/27 | ENST00000003084.11 | NP_000483.3 | |
| CFTR-AS1 | NR_149084.1 | n.221+1185G>A | intron_variant |
Ensembl
Frequencies
GnomAD3 genomes 0.00000657 AC: 1AN: 152104Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
1
AN:
152104
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251326Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135838
GnomAD3 exomes
AF:
AC:
5
AN:
251326
Hom.:
AF XY:
AC XY:
0
AN XY:
135838
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000644 AC: 94AN: 1459318Hom.: 0 Cov.: 30 AF XY: 0.0000510 AC XY: 37AN XY: 726132
GnomAD4 exome
AF:
AC:
94
AN:
1459318
Hom.:
Cov.:
30
AF XY:
AC XY:
37
AN XY:
726132
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome 0.00000657 AC: 1AN: 152104Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74300
GnomAD4 genome
AF:
AC:
1
AN:
152104
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74300
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:19Other:1
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Cystic fibrosis Pathogenic:10Other:1
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 19, 2021 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 14, 2016 | Variant summary: The variant of interest causes a nonsense change involving a conserved nucleotide resulting in a predicted truncated CFTR protein, a known mechanism for disease. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 2/121326 (1/60663), which does not exceed the predicted maximum expected allele frequency for a pathogenic CFTR variant of 1/77. The variant of interest has been reported in multiple affected individuals via publications, along with multiple reputable clinical laboratories/databases cite the variant as "pathogenic." Therefore, taking all available lines of evidence into consideration, the variant of interest is classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | curation | CFTR-France | Jan 29, 2018 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 13, 2022 | The p.Q493* pathogenic mutation (also known as c.1477C>T), located in coding exon 11 of the CFTR gene, results from a C to T substitution at nucleotide position 1477. This changes the amino acid from a glutamine to a stop codon within coding exon 11. This mutation was originally described in an individual with cystic fibrosis (clinical criteria were not provided) and pancreatic insufficiency (Kerem BS et al. Proc. Natl. Acad. Sci. U.S.A., 1990 Nov;87:8447-51). This mutation was also observed in conjunction with the (TG)12-5T variant in a male with congenital bilateral absence of the vas deferens (CBAVD); however, phase was not determined (Steiner B et al. Hum. Mutat., 2011 Aug;32:912-20). This mutation is associated with pancreatic insufficiency, pulmonary disease, and elevated sweat chloride levels (Sosnay PR et al. Nat. Genet., 2013 Oct;45:1160-7). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Aug 15, 2017 | The CFTR c.1477C>T (p.Gln493Ter) stop-gained variant has been reported in at least four studies and is found in a total of six affected individuals including four compound heterozygotes, one complex heterozygote, and one presumed heterozygote (Kerem et al. 1990; Kristidis et al. 1992; Feuillet-Fieux et al. 2011; Steiner et al. 2011). Three of the compound heterozygotes have a clinical diagnosis of cystic fibrosis and pancreatic insufficiency and have the p.Phe508del variant as their second variant (Kristidis et al. 1992). Steiner et al. (2011) reported on a compound heterozygote with a diagnosis of congenital bilateral absence of the vas deferens. Feuillet-Fieux et al. (2011) identified a complex heterozygous individual, with a clinical diagnosis of cystic fibrosis based on sweat chloride values who had no other pulmonary or intestinal symptoms, who carried three other variants on the maternal allele and the p.Gln493Ter variant on the paternal allele. The p.Gln493Ter variant was absent from 2456 controls and is reported at a frequency of 0.000047 in the European (non-Finnish) population of the Genome Aggregation Database. Due to the potential impact of stop-gained variants and the evidence available, the p.Gln493Ter variant is classified as pathogenic for CFTR-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Apr 22, 2020 | Disease-causing CFTR variant. See www.CFTR2.org for phenotype information. - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 1990 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 26, 2024 | This sequence change creates a premature translational stop signal (p.Gln493*) in the CFTR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). This variant is present in population databases (rs77101217, gnomAD 0.005%). This premature translational stop signal has been observed in individual(s) with cystic fibrosis (PMID: 1376016, 2236053, 12815607, 21184098, 21858268, 23974870). ClinVar contains an entry for this variant (Variation ID: 7107). For these reasons, this variant has been classified as Pathogenic. - |
| not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | Variant interpreted as Pathogenic and reported on 09-23-2020 by Lab or GTR ID 500068. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
| Pathogenic, reviewed by expert panel | research | CFTR2 | Mar 17, 2017 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 11, 2019 | NM_000492.3(CFTR):c.1477C>T(Q493*) is classified as pathogenic in the context of cystic fibrosis and is associated with the classic form of disease. Sources cited for classification include the following: PMID 23974870 and 18456578. Classification of NM_000492.3(CFTR):c.1477C>T(Q493*) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening.‚Äã - |
not provided Pathogenic:4
| Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 10, 2023 | The CFTR c.1477C>T; p.Gln493Ter variant (rs77101217) has been reported in cystic fibrosis patients, often associated with pancreatic insufficiency (CFTR2 database, Kerem 1990, Ooi 2012, Sosnay 2013). This variant is also reported in ClinVar (Variation ID: 7107). It is only found on six alleles in the Genome Aggregation Database (v2.1.1), indicating it is not a common polymorphism. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: CFTR2 database: http://cftr2.org/ Kerem BS et al. Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8447-51. PMID: 2236053. Ooi CY et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst Fibros. 2012 Sep;11(5):355-62. PMID: 22658665. Sosnay PR et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013 Oct;45(10):1160-7. PMID: 23974870. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 15, 2018 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 08, 2021 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Aug 10, 2022 | - - |
CFTR-related disorder Pathogenic:1
| Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 17, 2017 | - - |
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Cystic fibrosis;C0238339:Hereditary pancreatitis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation;C2749757:Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 17, 2024 | - - |
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 19, 2024 | - - |
Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Dec 23, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at